P2.03a-022 QOL and Febrile Neutropenia: Japanese Phase 2 Trial of Docetaxel with/out Antiangiogenic Agent in 2nd Line NSCLC

Yukie Omori; Alan Brnabic; Narayan Rajan; Jangchul Park; Sotaro Enatsu; Akira Inoue

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >P2.03a-022 QOL and Febrile Neutropenia: Japanese Phase 2 Trial of Docetaxel with/out Antiangiogenic Agent in 2nd Line NSCLC

【24h】

P2.03a-022 QOL and Febrile Neutropenia: Japanese Phase 2 Trial of Docetaxel with/out Antiangiogenic Agent in 2nd Line NSCLC

机译：P2.03A-022 QOL和Febrile Neveropenia：日语第2阶段试验多西紫杉醇/输出抗挂剂的第二线NSCLC

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2017年第1期|共1页
作者
Yukie Omori; Alan Brnabic; Narayan Rajan; Jangchul Park; Sotaro Enatsu; Akira Inoue;
展开▼
作者单位

Eli Lilly Japan K.K.;

Eli Lilly Australia Pty. Limited;

Eli Lilly Australia Pty. Limited;

Eli Lilly Japan K.K.;

Eli Lilly Japan K.K.;

Tohoku University;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献

1. P2.03a-022 QOL and Febrile Neutropenia: Japanese Phase 2 Trial of Docetaxel with/out Antiangiogenic Agent in 2nd Line NSCLC [J] . Yukie Omori, Alan Brnabic, Narayan Rajan, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：P2.03A-022 QOL和Febrile Neveropenia：日语第2阶段试验多西紫杉醇/输出抗挂剂的第二线NSCLC
2. P2.03a-022 QOL and Febrile Neutropenia: Japanese Phase 2 Trial of Docetaxel with/out Antiangiogenic Agent in 2nd Line NSCLC [J] . Yukie Omori, Alan Brnabic, Narayan Rajan, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：P2.03A-022 QOL和Febrile Neveropenia：日语第2阶段试验多西紫杉醇/输出抗挂剂的第二线NSCLC
3. The Relevance of Docetaxel-related Febrile Neutropenia to Patient-reported Symptoms and the Quality of Life in Japanese, East Asian (Korean, Taiwanese), and Non-East Asian Patients Based on Post-hoc Analyses of Two Randomized Clinical Trials of Docetaxel with and Without Anti-angiogenic Agent in Advanced Non-small Cell Lung Cancer After Progression on Platinum-based Chemotherapy [J] . Yukie Omori1, Sotaro Enatsu1, Alan J.M. Brnabic, 肺癌 . 2019,第7期

机译：与多西紫杉醇的两次随机临床试验的后HOC分析，多西紫杉醇相关的FERESOPENIA对患者报告的症状和日本人的生活质量和生活质量的相关性。在铂基化疗的进展后，不含抗血管生成剂在先进的非小细胞肺癌中
4. PHASE I/II TRIAL OF DUAL AGENT POLYAMINE DEPLETION THERAPY FOR FELINE ORAL SQUAMOUS CELL CARCINOMA [C] . Katherine A Skorupski, Thomas OBrien, Mark Burns, Annual conference of the Veterinary Cancer Society . 2008

机译：双药剂多胺耗竭治疗猫鳞状鳞状细胞癌的I / II试验
5. Preclinical pharmacokinetic and tolerance assessment and phase I clinical trial of MU-Gold, a novel chemotherapeutic agent. [D] . Higginbotham, Mary Lynn. 2004

机译：新型化学治疗剂MU-Gold的临床前药代动力学和耐受性评估以及I期临床试验。
6. Phase III placebo-controlled double-blind randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy [O] . Yoshimasa Kosaka, Yoshiaki Rai, Norikazu Masuda, -1

机译：接受多西他赛/环磷酰胺化疗的乳腺癌患者接受培格非司亭治疗的安慰剂对照双盲随机试验以降低发热性中性粒细胞减少的风险

P2.03a-022 QOL and Febrile Neutropenia: Japanese Phase 2 Trial of Docetaxel with/out Antiangiogenic Agent in 2nd Line NSCLC

著录项

相似文献

相关主题

期刊订阅